coming back to life ?

Hello everyone. What do people think of yesterday's results?

A tad disapointing , we were all used to knock out results it seems , but still positve over all.
Myconate works even on already high yeilding fields it seems , I believe a partnering deal is just around the corner.

you could say that!!!!

I didn't think it would be the very next day, but i'm not complaining.

I find it strange that shares mag haven't mentioned PHC since the deal.
Wonder why.

All good news this morning, final results sales up, successful harpins trial, and in supply talks with four companies for myconate and harpins technology
Off we go again!!!!!

Yep were off!!!!!!

With the recent news and the RSI starting to look top heavy, any pullback would be a good time to top up as further deals could come thick and fast (imo)

More excellent trial results.

Plant Health Care PLC
27 June 2007


Embargoed until 7AM, 27 June 2007


Plant Health Care plc
Myconate(R) produces outstanding yield gains in wheat.


Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, is pleased to report the first independent results of its
Myconate(R) testing programmes in wheat. Following impressive results in many
and varied crops over the past several years, the results of these trials now
demonstrate the effectiveness of Myconate(R) in a new class of crops - the small
cereal grains. The Company now has compelling evidence of yield stimulation in
the two most important representatives of this class: wheat and sorghum.

During the 2006/2007 season, Myconate(R) was evaluated in three separate
independent wheat trials in Mexico; two in Baja and one in Sonora. These trials
were conducted by local farmers and distributed across a wide range of soil and
climate conditions for this crop.

In the Baja trials, the yield increases at the two locations were 21% and 16%;
this resulted in increased income for the grower of US$385 per hectare and
US$326 per hectare respectively. In these cases the trials involved large plot
sizes of 4 hectares (10 acres) so the response has been proven on growers farms
in a full commercial setting.

In Sonora, the trials were established to determine the effect of seed rate and
Myconate coating. In this test 20% less seed was planted in the Myconate treated
fields. The yield from both the control field and the Myconate reduced seed
fields were essentially identical (approximately a 23% yield increase on the
Myconate treated field when adjusted for seed rate) and the protein content of
the Myconate(R) treated wheat was increased by 8.5%. As a result, the increased
income to the grower for the higher yield and higher protein content would be
around US$600 per hectare.

Further results of our cereal testing including more wheat, sorghum and barley
trials are expected as the year progresses.

John Brady, CEO of Plant Health Care commented on the results, 'Once again
Myconate has proven its ability to consistently deliver improved yields in a
variety of crops and under differing soil and climatic conditions. We are
especially pleased to now have large scale tests results on the important cereal
grain crops which number in excess of 300 million acres in the North America,
Europe, South America and Southern Africa regions. All of this coincides with
planned timing for further Myconate supply agreements.'

Myconate background
Through the stimulation of endogenous mycorrhizal fungi, PHC's novel Myconate
technology helps crops to develop larger effective rooting volume. Myconate
works by triggering the germination and growth of beneficial micro-organisms
called mycorrhizal fungi which colonize the roots of crop plants. With more
mycorrhizal fungi at work, each plant can draw more nutrients and moisture out
of the soil. More nutrients make for healthier plants, and significantly
greater overall yields. The Board believes Myconate could be the key to
changing the face of farming. The safety and ease of application of Myconate
means that management practices need not be over-hauled. The procedure is a
straightforward blending process, either tank mixing the Myconate with the
fertilizer during planting, or applying the Myconate to the seed before
planting.


For further information please contact:

Plant Heath Care plc Tavistock Communications
John Brady, Chief Executive Jeremy Carey / Simon Compton
Tel: 001 603 525 3702 Tel: 020 7920 3150

Evolution Securities Limited
Tim Worlledge / Tim Redfern
Tel: 020 7071 4312



This information is provided by RNS
The company news service from the London Stock Exchange
ND
MSCUNSWRBBRNUAR

Plant Health Care PLC
24 September 2007

Embargoed until 7.00 24 September 2007



PLANT HEALTH CARE PLC

('Plant Health Care' or 'the Company')


Myconate Field Trial Update


- Significant yield improvement demonstrated on a variety of crops -


Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, is pleased to report the success of recent Myconate tests. The
trials, which were all undertaken in the US, are part of the extensive
development programme underway and further reinforce the commercial potential of
Myconate.

When applied to carrots in furrow application at seeding, Myconate produced a
resultant yield improvement in excess of 30% in two separate trials. Both trials
were carried out independently by a major Wisconsin vegetable grower.

Celery trials in Wisconsin demonstrated a 14% harvestable yield increase when
Myconate was applied as a pre-plant, transplant spray. Against the control,
tests showed a 12% increase in total weight and 12% increase in top weight. A
13% yield increase was achieved in trials on onions and, as with celery,
application was by pre-plant, transplant spray. Additionally, a 13% increase in
bulb weight and 11% increase in diameter were recorded.

The results of Myconate trials on grain and straw in winter wheat, tested using
a variety of applications and produced particularly pleasing yield improvements.
When applied as a seed treatment yield increased as much as 5.4% and when
applied as a ground spray the improvement was up to 7.4%. Additionally,
Myconate's application as both a seed treatment and a ground spray delivered
yield increases of up to 9.4%.


Commenting on the trials, John Brady, Chief Executive of Plant Health Care,
said:

'The increase in yields on grain and straw in severe winter conditions are very
pleasing and the results of these tests are compelling, confirming Myconate's
efficacy through a number of applications. The results achieved highlight the
opportunity Myconate presents on a broad range of crops and vegetables. We are
committed to delivering shareholder value through the commercialisation of our
natural technologies and the ongoing development and marketing of Myconate and
Harpin is central to our strategy.'


-Ends-

Plant Health Care PLC
27 September 2007


Embargoed until 0700, 27 September 2007



PLANT HEALTH CARE PLC


Plant Health Care plc ('the Company' or 'Plant Health Care')


5 Million Equity Placing


Plant Health Care plc, the provider of natural products for plant and soil care,
announces that it has raised 4,993,240 (before expenses) by way of a placing of
2,098,000 new ordinary shares at a price of 238 pence per share ('Placing
Shares'). The Placing Shares have been placed with existing shareholders by
Evolution Securities, the Company's Nominated Adviser and broker.

As stated in the Company's interim results released on 24 September 2007, the
Company currently has net cash balances of approximately US$2.0 million as well
as credit facilities in place adequate for its current needs. However, following
discussions with a number of the Company's major shareholders, the Board has
decided that it would be appropriate to take the opportunity to strengthen its
balance sheet and to provide additional resources to accelerate the momentum
which has been achieved as regards the commercialisation of Myconate and Harpin.

The placing is conditional only upon Admission of the Placing Shares to AIM.
Application will be made for the Placing Shares, which rank pari passu with the
existing issued trading shares, to be admitted to trading on AIM and dealings
are expected to commence on Tuesday, 2 October 2007.

John Brady, Chief Executive, commented:

'We are very pleased with the progress we have made towards the
commercialisation of Myconate and Harpin; these additional funds enable us to
invest in the resources necessary to accelerate development'.

He added: 'We are very appreciative of the support given by our shareholders'.

Always a good sign.

Plant Health Care PLC
22 October 2007


TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached (ii):

PLANT HEALTH CARE plc

2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (NO)

An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached: (NO)

An event changing the breakdown of voting rights: (NO)
Other (please specify): (YES - Issued Share Capital Adjustment)

3. Full name of person(s) subject to the notification obligation (iii):

Gartmore Investment Limited

4. Full name of shareholder(s) (if different from 3.) (iv):

See attached schedule

5. Date of the transaction (and date on which the threshold is crossed or
reached if different) (v):

28/09/2007

6. Date on which issuer notified:

01/10/2007

7. Threshold(s) that is/are crossed or reached:
9%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares if Situation previous to the Triggering transaction (vi)
possible using the ISIN
CODE
Number of Number of
shares voting Rights
(viii)

GB00B01JC540 3,415,820 3,415,820

Resulting situation after the triggering transaction (vii)
Class/type of Number of Number of voting rights (ix) % of voting rights
shares if shares
possible using
the ISIN CODE
Direct (x) Indirect (xi) Direct Indirect
GB00B01JC540 3,983,820 3,983,820 9.470%

B: Financial Instruments

Resulting situation after the triggering transaction (xii)
Type of Expiration Exercise/ Number of voting rights that may % of
financial Date Conversion be acquired if the instrument is voting
instrument (xiii) Period/Date exercised/ converted. rights
(xiv)

Total (A+B)

Number of % of voting
voting rights rights

3,983,820 9.470%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments
are effectively held, if applicable (xv):

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

All shares are held indirectly. All figures are based on the company's issued
share capital of 42,069,375 as provided by Exshare.

Nice up move today!

More good news, Plant Health Care is looking pretty solid (imo).


Plant Health Care PLC
12 December 2007


PLANT HEALTH CARE PLC

('Plant Health Care' or 'the Company')

Plant Health Care and Monsanto sign agreement for the development and
commercialization of Harpin Technology

Plant Health Care Inc, a wholly-owned subsidiary of Plant Health Care plc (AIM:
PHC), and Monsanto Company (NYSE: MON) have entered into an agreement to
evaluate, develop and commercialize applications of Plant Health Care's
Harpin-based technology.

Plant Health Care's Harpin seed technology is aimed at suppressing nematodes in
crop settings. Under the agreement, Plant Health Care will grant Monsanto
certain exclusive rights to applications of its Harpin technology. In return
Plant Health Care will receive an undisclosed upfront payment, plus a milestone
payment dependent upon the progress of the development of the technology over
the next twelve months.

Once evaluations are complete, the companies estimate that the products could be
available to farmers by the end of the decade. At the time of commercialization,
Plant Health Care will also receive a royalty payment based on the acreage for
which the Harpin technology is supplied. Additional terms of the agreement were
not disclosed at this time.

John Brady, CEO of Plant Health Care, noted: 'This agreement represents a
significant step forward in the development of our company and provides an ideal
first platform for the Harpin technology. This agreement with Monsanto validates
the confidence that our Board has in the Harpin technology which we only
acquired earlier this year.'

About Monsanto Company
Monsanto Company is a leading global provider of technology-based solutions and
agricultural products that improve farm productivity and food quality. For more
information, please visit the company's web site at
www.monsanto.com
.

About Plant Health Care plc
Plant Health Care plc ('PHC') is a leading provider of natural products for
plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United
States, PHC currently has approximately 70 employees and has operations in the
United States, Mexico, the United Kingdom, Spain, and the Netherlands. The
Company listed on the AIM market of the London Stock Exchange in July 2004.
Ticker symbol is PHC.

PHC's products are aimed at the landscape, agriculture and land reclamation
industries and are environmentally beneficial. Through the commercialization of
these products, PHC is capitalizing on current long-term trends toward natural
systems and biological products for plant care and soil and water management.
Further information is available at:
www.planthealthcare.com

Plant Health Care PLC
19 December 2007


TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached (ii):

PLANT HEALTH CARE plc

2. Reason for the notification (please state Yes/No): ( )

An acquisition or disposal of voting rights: (YES)

An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached: ( )

An event changing the breakdown of voting rights: ( )

Other (please specify): ()

3. Full name of person(s) subject to the notification obligation (iii):


Aviva plc & its subsidiaries


4. Full name of shareholder(s) (if different from 3.) (iv):

Registerd holder:

CUIM Nominee Limited 61,265*

* denotes direct interest

Delta Lloyd Luxembourg Water & Climate Fund 146,000

Kadoorie McAuley International Limited 12,400

Ohra Milieutechnologie Fonds NV 132,500

Triodos Value Pioneer Fund 137,500

Vidacos Nominees Limited 1,838,816



5. Date of the transaction (and date on which the threshold is crossed or
reached if different) (v):


12 December 2007


6. Date on which issuer notified:

14 December 2007



7. Threshold(s) that is/are crossed or reached:


Below 5% to 5% Change at Combined Interest level



8. Notified details:

A: Voting rights attached to shares

Class/type of shares if Situation previous to the Triggering transaction (vi)
possible using the ISIN
CODE
Number of Number of
shares voting Rights
(viii)


GB00B01JC540 Below 5% Below 5%


Resulting situation after the triggering transaction (vii)
Class/type of Number of Number of voting rights (ix) % of voting rights
shares if possible shares
using the ISIN
CODE

Direct Direct (x) Indirect (xi) Direct Indirect


GB00B01JC540 61,265 61,265 2,267,216 0.14% 5.13%



B: Financial Instruments


Resulting situation after the triggering transaction (xii)

Type of Expiration Exercise/ Number of voting rights that may % of
financial Date Conversion be acquired if the instrument is voting
instrument (xiii) Period/Date exercised/ converted. rights
(xiv)



Total (A+B)


Number of % of voting
voting rights rights


2,328,481 5.27%



9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments
are effectively held, if applicable (xv):

See Section 4

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

Figures are based on a total number of voting rights of 44,214,229.

14. Contact name:

(i) Andrew Wood FCIS, Company Secretary

(II) Tim Redfern, Evolution Securities Limited

(iii) Jeremy Carey, Tavistock Communications

15. Contact telephone number:

(i) +44 (0)20 8866 5702
(ii) +44 (0)20 7071 4300
(iii) +44 (0)20 7920 3150

Annex to Notification Of Major Interests In Shares (xvi)

A: Identity of the person or legal entity subject to the notification obligation

Full name (including legal form for legal entities):

Aviva plc

Contact address (registered office for legal entities):

St Helen's, 1 Undershaft, London EC3P 3DQ

Phone number:

01603 684420

Other useful information (at least legal representative for legal persons):

Neil Whittaker

B: Identity of the notifier, if applicable (xvii)

Full name:

Contact address:


Phone number:

Other useful information (e.g. functional relationship with the person or legal
entity subject to the notification obligation)

END


19 December 2007

Plant Health Care PLC
09 January 2008



EMBARGOED: 09.00, 9 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Field Trials Update

- Strong commercial field trial results in Harpin based N-Hibit and ProAct -

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, will announce today, at the Beltwide Cotton Conferences in
Nashville, Tennessee that results of replicated N-Hibit(R) and ProActTM field
trials in 2007 demonstrated yield improvements in cotton of between 6% and 12%
when used in combination with nematicides.

N-Hibit(R) and ProActTM are EPA registered, Harpin based products which have, in
field trials, consistently demonstrated their efficacy in improving crop yields
by reducing harmful cyst nematodes. Harpin proteins are produced by diseases
which are harmful to plants and, as a result, the application of a Harpin based
technology, such as N-Hibit(R) or ProActTM, causes the plant to behave as though
being attacked, even in the absence of disease pressure. Consequently, the plant
activates its natural self-defence and growth system, improving yield, root mass
and overall plant biomass.

Plant Health Care develops, manufacturers and markets a range of innovative
Harpin Protein-based products (Harp-N-Tek(R)). Harpin based proteins have
demonstrated a reduction in nematode populations by on average 50 percent, in
numerous replicated and commercial field testing work undertaken over several
years by leading university plant pathologists and nematologists, crop
consultants and cotton producers.

Commenting on the trials, John Brady, Chief Executive of Plant Health Care,
said:

'In the Company's interim results statement, the board highlighted its belief in
the substantial commercial potential for our Harpin technology and undertaking
trials is an important part of the development process. The agreement signed
with Monsanto in December 2007, was a significant step in developing this
exciting technology and the success of these trials further validates the
board's belief in its potential.'

'In demonstrating such strong yield improvements in these recent tests,
particularly in conjunction with other, already established and widely used
nematicides, the prospects for Harpin are further strengthened and the board
will continue to explore opportunities available to it in order to exploit fully
the potential of this exciting technology.'

-Ends-

A good company, and a good looking chart to match.
Next stop 3 perhaps?

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Product Update

Advance towards commercialisation of Myconate(R) in cereal crops

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soils, is pleased to report that, based on the very encouraging
results of its 2007 Myconate(R) test programs in cereals, it has reached
agreement, on a non-exclusive basis, with several large, multi-national
agrochemical/seed companies to move forward in 2008 with testing and potential
commercialisation of Myconate(R) in cereal grain crops such as wheat, barley,
sorghum and oats. The testing partners were selected because of their
geographical reach and significant market share in the cereal grain markets.

These arrangements are a result of the outcome from the first independent tests
of Plant Health Care's Myconate(R) programmes in wheat and barley in the USA.
Following the impressive results demonstrated in wheat in Mexico, reported on 27
June 2007, the latest results demonstrate the efficacy of Myconate(R) in both
winter and spring sown wheat and in spring sown barley. Plant Health Care now
has compelling evidence of yield improvement, when Myconate(R) is applied to
three important representatives of the small cereal grains: wheat, barley and
sorghum.

Winter wheat grain yields were increased across five locations by a range of
5.4% to 9.4% depending on application method, timing and quantity applied.
Spring sown wheat and barley yields were increased by 5.9% and 11.9%
respectively. The results also demonstrated that yield gain was attributable to
increases in both grain number and grain weight.

The forthcoming extensive evaluations will be carried out during 2008. The
Company believes that the test partners, being large global businesses operating
in the agrochemical and/or seed markets, each has the capabilities to conduct
trials, and ultimately commercialise Myconate(R) across cereal crops in Europe,
the Americas and Australia/Asia.

John Brady, Chief Executive of Plant Health Care commented on the results: 'We
are extremely excited to be working with these global companies to develop a
path to commercialisation for Myconate(R) in these very important crops. Due to
the more regional nature of cereal grains we have opted not to grant an
exclusive agreement as we have in the past but have elected to move forward with
several testing partners who have historically demonstrated strengths in each
market.'

'These recent cereal grain tests demonstrated the ability of Myconate(R) to be
effective in a range of climatic conditions and provided us with important data
points when determining the optimal dose rates and timing for application.'

For further information please contact:

Plant Heath Care plc Tavistock Communications
John Brady, Chief Executive Jeremy Carey / Matt Ridsdale
Tel: 020 7920 3150 (21-25 January) Tel: 020 7920 3150
Tel: 001 603 525 3702 (Thereafter)

Evolution Securities Limited
Tim Worlledge / Tim Redfern
Tel: 020 7071 4300

Myconate(R) background
Through the stimulation of endogenous mycorrhizal fungi, PHC's novel Myconate(R)
technology helps crops to develop larger effective rooting volume. Myconate(R)
works by enhancing the growth of beneficial micro-organisms called mycorrhizal
fungi which colonize the roots of crop plants. With more mycorrhizal fungi at
work, each plant can draw more nutrients and moisture out of the soil. More
nutrients make for healthier plants, and significantly greater overall yields.
Plant Health Care believes Myconate(R) could be the key to changing the face of
farming. The safety and ease of application of Myconate(R) means that management
practices need not be over-hauled. The procedure is a straightforward blending
process, either tank mixing the Myconate(R) with the fertilizer during planting,
or applying the Myconate(R) to the seed before planting.

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Trading Update

Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, provides a post year end update for 2007, ahead of the
announcement of its Preliminary Results in late March/early April 2008.

The Company has also announced today that following the 2007 Myconate(R) trial
results, Bayer CropScience has confirmed that it will move forward with the
second year of Myconate(R) testing. Bayer CropScience will be making a milestone
payment to Plant Health Care for the continuation of the cooperation into the
second year.

In addition, the Company has announced today that following very encouraging
results of its 2007 Myconate(R) testing programme in cereal crops it is moving
forward, in 2008, with further testing and commercialisation activities for the
application of Myconate(R) on cereal grain crops with several large,
international agrichemical and/or seed companies.

Plant Health Care's turnover for the year ended 31 December 2007 is expected to
be $18.4 million, up 35% on the prior year. Following significant investment in
market development of Myconate(R) and Harpin, the operating loss for the period
is expected to be approximately $4.4 million. In addition, it is expected that
there will be non-operating charges of approximately $0.8 million of which
approximately $0.4 million relates to amortisation of the value of executive
share incentives awarded and is a non-cash item. As a result, the loss before
tax for the period is expected to be approximately $5.3 million. At 31 December
2007, the Company had cash and cash equivalents of approximately $10.8 million.

In terms of turnover, 5% relates to licensing and milestone payments from
partners. The marginally higher than expected operating loss in 2007 is largely
due to an important Harpin deal being delayed. The directors now anticipate that
this deal, with one of the world's leading agrichemical companies, will be
completed in the first half of 2008.

Commenting, John Brady, Chief Executive of Plant Health Care said: 'In January
2007 we signed our first development and commercialisation agreement for
Myconate(R) with Bayer CropScience and in December we secured our first
agreement for our EPA-registered Harpin technology with Monsanto. These two
agreements represent very significant progress for our Company.

'I am very pleased with the advance made during 2007 as our Company continues to
move forward in its efforts of establishing the necessary channels to extract
considerable value from our natural technologies.'

-Ends-

Plant Health Care PLC
21 January 2008



For release: 21 January 2008

PLANT HEALTH CARE PLC
('Plant Health Care' or 'the Company')

Bayer CropScience moves forward with second year of Myconate(R) tests


Plant Health Care (AIM: PHC.L), a leading provider of natural products for
plants and soil, announces that following the 2007 trial results, Bayer
CropScience has confirmed that it will move forward with the second year of
Myconate(R) testing. Bayer CropScience will be making a milestone payment to
Plant Health Care for the continuation of the cooperation into the second year.
Financial details were not disclosed.

Bayer CropScience, the global leader in seed treatment products, offers a broad
portfolio of high-quality products to combat pests and fungal diseases. Plant
Health Care's Myconate(R) technology is known to help crops to develop larger
root mass through the stimulation of naturally occurring mycorrhizal fungi,
which in turn often leads to improved yields and enhanced stress resistance.
Both companies are collaborating on the further development of Myconate(R) as a
seed treatment product in corn, soybean, cotton and sunflower on a worldwide
basis.

Commenting, John Brady, Chief Executive of Plant Health Care said: 'We are
excited that Bayer CropScience has elected to move forward with the development
and trial programme and we look forward to working with them to further develop
the commercial potential of Myconate(R).'

-Ends-